Friday, July 10, 2026

pharma · Hepatocellular Carcinoma · Liver Cancer

Chinese PLA General

Chinese PLA General clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
4
Drugs
9
Patents
0
Intelligence · Clinical Programs

Chinese PLA General projects

2 ClinicalTrials.gov programs sponsored by Chinese PLA General.

Chinese PLA General has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. anti-CD133-CAR vector-transduced T cells

    Chinese PLA General Hospital

    Liver Cancer

    phase 2 mab completed

    1 trial
  2. raltitrexed combined with apatinib

    Chinese PLA General Hospital

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Chinese PLA General have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.